Stability of extemporaneously prepared sodium phenylbutyrate oral suspensions

American Journal of Health-System Pharmacy

Volumn 64, Issue 14, 2007, Pages 1513-1515

  Caruthers, Regine L ^a,b   Johnson, Cary E ^c,d  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Department of Pharmacy Practice   (United States)

^d UMHHC   (United States)

Author keywords

Antihyperammonemic agents; Color; Compounding; Concentration; Contamination; Hydrogen ion concentration; Odors; Sodium phenylbutyrate; Stability; Storage; Suspensions; Taste; Vehicles

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; DRUG ADDITIVE; ORA PLUS; ORA SWEET; SODIUM DERIVATIVE; SODIUM PHENYLBUTYRATE; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; COLOR; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG PACKAGING; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ODOR; PH; PRIORITY JOURNAL; ROOM TEMPERATURE; SUSPENSION; TASTE;

EID: 34447545864     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060450     Document Type: Article

References (5)

1. Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr. 2001; 138:S46-55.
2. Buphenyl (sodium phenylbutyrate) package insert. Scottsdale, AZ: Ucyclyd Pharma; 2003 Aug.
3. Feillet F, Leonard JV. Alternative pathway therapy for urea cycle disorders. J Inherit Metab Dis. 1998; 21(suppl 1):101-11.
4. Sodium phenylbutyrate: pediatric drug information. UpToDate. Lexi-Comp, Inc. (accessed 2006 Mar 29).
5. Brusilow SW. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr Res. 1991; 29:147-50.